Accepted for/Published in: JMIR Research Protocols
Date Submitted: Feb 14, 2022
Open Peer Review Period: Feb 14, 2022 - Apr 11, 2022
Date Accepted: May 27, 2022
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Phase IV clinical trial with a single treatment arm to evaluate bronchopulmonary penetration of isavuconazole in pulmonary transplant recipients (PBISA01): Study protocol clinical trial.
ABSTRACT
Background:
Aspergillosis is the most frequently observed invasive fungal disease (IFD) in lung transplant recipients. Isavuconazole has shown a better safety profile and non-inferiority to voriconazole in the treatment of patients with IFD.
Objective:
The aim of this study is to describe the bronchopulmonary pharmacokinetic profile of oral isavuconazole by analyzing the degree of penetration in the epithelial lining fluid and the alveolar macrophages in patients receiving lung transplantation with a diagnosis of invasive fungal disease.
Methods:
A total of 12 patients over 18 years of age, lung transplant recipients with IFD diagnosis and indication for isavuconazole treatment and follow-up bronchoscopy will be included in the study. After 5 days of treatment with isavuconazole and before the treatment is discontinued, patients will be randomized to perform the scheduled bronchoscopy at different times from the administration of Isavuconazole (2, 4, 8, 12 hours). Four blood samples will be obtained per patient: at 72 h after treatment initiation, the day of the bronchoscopy, at the time of the BAL (simultaneously) and 7 days after treatment initiation, in order to analyse tacrolimus and isavuconazole plasma levels. Isavuconazole concentrations will be measured in plasma, epithelial lining fluid (ELF) and alveolar macrophages (CA) by a high-performance liquid chromatography/UV couple to Fluorescence method.
Results:
Recruitment is ongoing. No preliminary data have been yet obtained.
Conclusions:
There are no clinical studies that analyze the bronchopulmonary penetration of isavuconazole. Bronchoalveolar lavage (BAL) performed routinely in the follow-up of lung transplant recipients, constitutes an opportunity to analyze the bronchopulmonary penetration of isavuconazole. Clinical Trial: This clinical trial has been registered on the European Clinical Trials Register (www.clinicaltrialsregister.eu), and the registration number is 2019-004240-30.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.